Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review

Destin Groff, Ashley Sun, Anna E Ssentongo, Djibril M Ba, Nicholas Parsons, Govinda R Poudel, Alain Lekoubou, John S Oh, Jessica E Ericson, Paddy Ssentongo, Vernon M Chinchilli, Destin Groff, Ashley Sun, Anna E Ssentongo, Djibril M Ba, Nicholas Parsons, Govinda R Poudel, Alain Lekoubou, John S Oh, Jessica E Ericson, Paddy Ssentongo, Vernon M Chinchilli

Abstract

Importance: Short-term and long-term persistent postacute sequelae of COVID-19 (PASC) have not been systematically evaluated. The incidence and evolution of PASC are dependent on time from infection, organ systems and tissue affected, vaccination status, variant of the virus, and geographic region.

Objective: To estimate organ system-specific frequency and evolution of PASC.

Evidence review: PubMed (MEDLINE), Scopus, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched from December 2019 through March 2021. A total of 2100 studies were identified from databases and through cited references. Studies providing data on PASC in children and adults were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for abstracting data were followed and performed independently by 2 reviewers. Quality was assessed using the Newcastle-Ottawa Scale for cohort studies. The main outcome was frequency of PASC diagnosed by (1) laboratory investigation, (2) radiologic pathology, and (3) clinical signs and symptoms. PASC were classified by organ system, ie, neurologic; cardiovascular; respiratory; digestive; dermatologic; and ear, nose, and throat as well as mental health, constitutional symptoms, and functional mobility.

Findings: From a total of 2100 studies identified, 57 studies with 250 351 survivors of COVID-19 met inclusion criteria. The mean (SD) age of survivors was 54.4 (8.9) years, 140 196 (56%) were male, and 197 777 (79%) were hospitalized during acute COVID-19. High-income countries contributed 45 studies (79%). The median (IQR) proportion of COVID-19 survivors experiencing at least 1 PASC was 54.0% (45.0%-69.0%; 13 studies) at 1 month (short-term), 55.0% (34.8%-65.5%; 38 studies) at 2 to 5 months (intermediate-term), and 54.0% (31.0%-67.0%; 9 studies) at 6 or more months (long-term). Most prevalent pulmonary sequelae, neurologic disorders, mental health disorders, functional mobility impairments, and general and constitutional symptoms were chest imaging abnormality (median [IQR], 62.2% [45.8%-76.5%]), difficulty concentrating (median [IQR], 23.8% [20.4%-25.9%]), generalized anxiety disorder (median [IQR], 29.6% [14.0%-44.0%]), general functional impairments (median [IQR], 44.0% [23.4%-62.6%]), and fatigue or muscle weakness (median [IQR], 37.5% [25.4%-54.5%]), respectively. Other frequently reported symptoms included cardiac, dermatologic, digestive, and ear, nose, and throat disorders.

Conclusions and relevance: In this systematic review, more than half of COVID-19 survivors experienced PASC 6 months after recovery. The most common PASC involved functional mobility impairments, pulmonary abnormalities, and mental health disorders. These long-term PASC effects occur on a scale that could overwhelm existing health care capacity, particularly in low- and middle-income countries.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ericson reported consulting for Allergan outside the submitted work. No other disclosures were reported.

Figures

Figure 1.. Studies Included Studying Postacute Sequelae…
Figure 1.. Studies Included Studying Postacute Sequelae of COVID-19 (PASC)
A, Scatterplot representing each study’s PASC frequency (%) plotted according to length of follow-up from baseline (in days), represented by a circle proportional to the study’s sample size and annotated according to country. B, Box plot representing the frequency of PASC reported by follow-up period. The horizontal bar in each box plot is the median value for the outcome of interest. The edges of the box represent the first and third quartiles. The width of the box is the IQR. The whiskers extend to the smallest and largest observations within 1.5 times the IQR of the quartiles. The circles represent point estimates for each study included in the analysis. Circles extending beyond the whiskers are outliers.
Figure 2.. Neurologic, Mental Health, Respiratory, Mobility,…
Figure 2.. Neurologic, Mental Health, Respiratory, Mobility, and General Postacute Sequelae of COVID-19 (PASC) Symptoms
The vertical bar in each box plot is the median value for the outcome of interest. The edges of the box represent the first and third quartiles. The width of the box is the IQR. The whiskers extend to the smallest and largest observations within 1.5 times the IQR of the quartiles. The diamonds represent point estimates for each study included in the analysis. Diamonds extending beyond the whiskers are outliers. PTSD indicates posttraumatic stress disorder.
Figure 3.. Cardiac, Digestive, Skin, and Ear,…
Figure 3.. Cardiac, Digestive, Skin, and Ear, Nose, and Throat (ENT) Postacute Sequelae of COVID-19 (PASC) Symptoms
The vertical bar in each box plot is the median value for the outcome of interest. The edges of the box represent the first and third quartiles. The width of the box is the IQR. The whiskers extend to the smallest and largest observations within 1.5 times the IQR of the quartiles. The diamonds represent point estimates for each study included in the analysis. Diamonds extending beyond the whiskers are outliers.

References

    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
    1. Nurchis MC, Pascucci D, Sapienza M, et al. . Impact of the burden of COVID-19 in Italy: results of disability-adjusted life years (DALYs) and productivity loss. Int J Environ Res Public Health. 2020;17(12):4233. doi:10.3390/ijerph17124233
    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
    1. Rando HM, Bennett TD, Byrd JB, et al. . Challenges in defining long COVID: striking differences across literature, electronic health records, and patient-reported information. medRxiv. Preprint published March 26, 2021. doi:10.1101/2021.03.20.21253896
    1. Parsons N, Outsikas A, Parish A, et al. . Modelling the anatomic distribution of neurologic events in patients with COVID-19: a systematic review of MRI findings. AJNR Am J Neuroradiol. 2021;42(7):1190-1195. doi:10.3174/ajnr.A7113
    1. Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576-578. doi:10.7326/M20-5661
    1. Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603
    1. Bergwerk M, Gonen T, Lustig Y, et al. . COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021. doi:10.1056/NEJMoa2109072
    1. Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252. doi:10.1001/jama.2020.22717
    1. Nalbandian A, Sehgal K, Gupta A, et al. . Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. doi:10.1038/s41591-021-01283-z
    1. Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(n71):n71. doi:10.1136/bmj.n71
    1. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa Hospital Research Institute; 2011.
    1. Hadley W. Ggplot2: Elegant Graphics for Data Analysis. Springer; 2016.
    1. Carvalho-Schneider C, Laurent E, Lemaignen A, et al. . Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258-263. doi:10.1016/j.cmi.2020.09.052
    1. Glück V, Grobecker S, Tydykov L, et al. . SARS-CoV-2–directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. Infection. 2021;49(4):739-746. doi:10.1007/s15010-021-01598-6
    1. Pellaud C, Grandmaison G, Pham Huu Thien HP, et al. . Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area—a retrospective cohort study. Swiss Med Wkly. 2020;150(2930):w20314. doi:10.4414/smw.2020.20314
    1. Akter F, Mannan A, Mehedi HMH, et al. . Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh. Diabetes Metab Syndr. 2020;14(6):2031-2038. doi:10.1016/j.dsx.2020.10.016
    1. Panda S, Mohamed A, Sikka K, et al. . Otolaryngologic manifestation and long-term outcome in mild COVID-19: experience from a tertiary care centre in India. Indian J Otolaryngol Head Neck Surg. 2020;73(1):1-6. doi:10.1007/s12070-020-02217-w
    1. Huang Y, Tan C, Wu J, et al. . Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163. doi:10.1186/s12931-020-01429-6
    1. Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, et al. . Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020;15(12):e0243882. doi:10.1371/journal.pone.0243882
    1. Poncet-Megemont L, Paris P, Tronchere A, et al. . High prevalence of headaches during COVID-19 infection: a retrospective cohort study. Headache. 2020;60(10):2578-2582. doi:10.1111/head.13923
    1. Weerahandi H, Hochman KA, Simon E, et al. . Post-discharge health status and symptoms in patients with severe COVID-19. J Gen Intern Med. 2021;36(3):738-745. doi:10.1007/s11606-020-06338-4
    1. Daher A, Balfanz P, Cornelissen C, et al. . Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. Respir Med. 2020;174:106197. doi:10.1016/j.rmed.2020.106197
    1. de Graaf MA, Antoni ML, Ter Kuile MM, et al. . Short-term outpatient follow-up of COVID-19 patients: a multidisciplinary approach. EClinicalMedicine. 2021;32:100731. doi:10.1016/j.eclinm.2021.100731
    1. Tomasoni D, Bai F, Castoldi R, et al. . Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy. J Med Virol. 2021;93(2):1175-1179. doi:10.1002/jmv.26459
    1. Chiesa-Estomba CM, Lechien JR, Radulesco T, et al. . Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol. 2020;27(11):2318-2321. doi:10.1111/ene.14440
    1. Méndez R, Balanzá-Martínez V, Luperdi SC, et al. . Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021;290:621-263. doi:10.1111/joim.13262
    1. Huang Y, Pinto MD, Borelli JL, et al. . COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. medRxiv. Preprint published March 5, 2021. doi:10.1101/2021.03.03.21252086
    1. Smet J, Stylemans D, Hanon S, Ilsen B, Verbanck S, Vanderhelst E. Clinical status and lung function 10 weeks after severe SARS-CoV-2 infection. Respir Med. 2021;176:106276. doi:10.1016/j.rmed.2020.106276
    1. Sonnweber T, Boehm A, Sahanic S, et al. . Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: a prospective observational cohort study. Respir Res. 2020;21(1):276. doi:10.1186/s12931-020-01546-2
    1. Vaira LA, Hopkins C, Petrocelli M, et al. . Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and prospective study. J Laryngol Otol. 2020;134(8):703-709. doi:10.1017/S0022215120001826
    1. Puntmann VO, Carerj ML, Wieters I, et al. . Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265-1273. doi:10.1001/jamacardio.2020.3557
    1. Rosales-Castillo A, de Los Ríos CG, García JDM. Persistent symptoms after acute COVID-19 infection: importance of follow-up. Medicina Clinica. 2021;156(1):35. doi:10.1016/j.medcli.2020.08.001
    1. Halpin SJ, McIvor C, Whyatt G, et al. . Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93(2):1013-1022. doi:10.1002/jmv.26368
    1. Islam N, Lewington S, Kharbanda RK, Davies J, Várnai KA, Lacey B. Sixty-day consequences of COVID-19 in patients discharged from hospital: an electronic health records study. Eur J Public Health. 2021;31(2):280-282. doi:10.1093/eurpub/ckab009
    1. D’Cruz RF, Waller MD, Perrin F, et al. . Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7(1):00655-02020. doi:10.1183/23120541.00655-2020
    1. Mandal S, Barnett J, Brill SE, et al. ; ARC Study Group . ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396-398. doi:10.1136/thoraxjnl-2020-215818
    1. Raman B, Cassar MP, Tunnicliffe EM, et al. . Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683. doi:10.1016/j.eclinm.2020.100683
    1. Shah AS, Wong AW, Hague CJ, et al. . A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402-404. doi:10.1136/thoraxjnl-2020-216308
    1. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. doi:10.1183/13993003.03276-2020
    1. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-Month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-427. doi:10.1016/S2215-0366(21)00084-5
    1. Tabatabaei SMH, Rajebi H, Moghaddas F, Ghasemiadl M, Talari H. Chest CT in COVID-19 pneumonia: what are the findings in mid-term follow-up? Emerg Radiol. 2020;27(6):711-719. doi:10.1007/s10140-020-01869-z
    1. Townsend L, Dyer AH, Jones K, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. doi:10.1371/journal.pone.0240784
    1. Janiri D, Carfì A, Kotzalidis GD, Bernabei R, Landi F, Sani G; Gemelli Against COVID-19 Post-Acute Care Study Group . Posttraumatic stress disorder in patients after severe COVID-19 infection. JAMA Psychiatry. 2021;78(5):567-569. doi:10.1001/jamapsychiatry.2021.0109
    1. van den Borst B, Peters JB, Brink M, et al. . Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020;ciaa1750. doi:10.1093/cid/ciaa1750
    1. Lerum TV, Aaløkken TM, Brønstad E, et al. . Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4):2003448. doi:10.1183/13993003.03448-2020
    1. Sibila O, Albacar N, Perea L, et al. . Lung function sequelae in COVID-19 patients 3 months after hospital discharge. Arch Bronconeumol. 2021;57(suppl 2):59-61. doi:10.1016/j.arbres.2021.01.036
    1. Arnold DT, Hamilton FW, Milne A, et al. . Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399-401. doi:10.1136/thoraxjnl-2020-216086
    1. Zhao YM, Shang YM, Song WB, et al. . Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi:10.1016/j.eclinm.2020.100463
    1. Weng J, Li Y, Li J, et al. . Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol Hepatol. 2021;6(5):344-346. doi:10.1016/S2468-1253(21)00076-5
    1. Xiong Q, Xu M, Li J, et al. . Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89-95. doi:10.1016/j.cmi.2020.09.023
    1. Liang L, Yang B, Jiang N, et al. . Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. 2020;35(47):e418. doi:10.3346/jkms.2020.35.e418
    1. Qu G, Zhen Q, Wang W, et al. . Health-related quality of life of COVID-19 patients after discharge: a multicenter follow-up study. J Clin Nurs. 2021;30(11-12):1742-1750. doi:10.1111/jocn.15733
    1. Sonnweber T, Sahanic S, Pizzini A, et al. . Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481. doi:10.1183/13993003.03481-2020
    1. Ugurlu BN, Akdogan O, Yilmaz YA, et al. . Quantitative evaluation and progress of olfactory dysfunction in COVID-19. Eur Arch Otorhinolaryngol. 2021;278(7):2363-2369. doi:10.1007/s00405-020-06516-4
    1. Peluso MJ, Kelly JD, Lu S, et al. . Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv. Preprint published March 13, 2021. doi:10.1101/2021.03.11.21252311
    1. Garrigues E, Janvier P, Kherabi Y, et al. . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4-e6. doi:10.1016/j.jinf.2020.08.029
    1. Bellan M, Soddu D, Balbo PE, et al. . Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4(1):e2036142-e2036142. doi:10.1001/jamanetworkopen.2020.36142
    1. Moreno-Pérez O, Merino E, Leon-Ramirez J-M, et al. ; COVID19-ALC research group . Post-acute COVID-19 syndrome: incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378-383. doi:10.1016/j.jinf.2021.01.004
    1. Guler SA, Ebner L, Aubry-Beigelman C, et al. . Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4):2003690. doi:10.1183/13993003.03690-2020
    1. Dennis A, Wamil M, Alberts J, et al. ; COVERSCAN study investigators . Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391. doi:10.1136/bmjopen-2020-048391
    1. Logue JK, Franko NM, McCulloch DJ, et al. . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830-e210830. doi:10.1001/jamanetworkopen.2021.0830
    1. Rauch B, Kern-Matschilles S, Haschka SJ, et al. . COVID-19-related symptoms 6 months after the infection—update on a prospective cohort study in Germany. medRxiv. Preprint published February 13, 2021. doi:10.1101/2021.02.12.21251619
    1. Trunfio M, Venuti F, Alladio F, et al. . Diagnostic SARS-CoV-2 cycle threshold value predicts disease severity, survival, and six-month sequelae in COVID-19 symptomatic patients. Viruses. 2021;13(2):281. doi:10.3390/v13020281
    1. Walle-Hansen MM, Ranhoff AH, Mellingsæter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. BMC Geriatr. 2021;21(1):199. doi:10.1186/s12877-021-02140-x
    1. Huang C, Huang L, Wang Y, et al. . 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8
    1. Han X, Fan Y, Alwalid O, et al. . Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177-E186. doi:10.1148/radiol.2021203153
    1. Taboada M, Moreno E, Cariñena A, et al. . Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth. 2021;126(3):e110-e113. doi:10.1016/j.bja.2020.12.007
    1. Forte G, Favieri F, Tambelli R, Casagrande M. COVID-19 pandemic in the Italian population: validation of a post-traumatic stress disorder questionnaire and prevalence of PTSD symptomatology. Int J Environ Res Public Health. 2020;17(11):4151. doi:10.3390/ijerph17114151
    1. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9):e2019686-e2019686. doi:10.1001/jamanetworkopen.2020.19686
    1. Oronsky B, Larson C, Hammond TC, et al. . A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021;1-9.
    1. Lan L, Xu D, Ye G, et al. . Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020;323(15):1502-1503. doi:10.1001/jama.2020.2783
    1. Ellul MA, Benjamin L, Singh B, et al. . Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767-783. doi:10.1016/S1474-4422(20)30221-0
    1. Colafrancesco S, Alessandri C, Conti F, Priori R. COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Autoimmun Rev. 2020;19(7):102573. doi:10.1016/j.autrev.2020.102573
    1. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995-998. doi:10.1021/acschemneuro.0c00122
    1. Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. . Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11(1):6283. doi:10.1038/s41598-021-85359-3
    1. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. doi:10.1371/journal.pone.0238215
    1. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026
    1. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417-e2111417. doi:10.1001/jamanetworkopen.2021.11417
    1. Sivan M, Taylor S. NICE guideline on long COVID. BMJ. 2020;371:m4938. doi:10.1136/bmj.m4938
    1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9
    1. Parsons N, Outsikas A, Parish A, et al. . Modelling the anatomic distribution of neurologic events in patients with COVID-19: a systematic review of MRI findings. AJNR Am J Neuroradiol. 2021;42(7):1190-1195. doi:10.3174/ajnr.A7113

Source: PubMed

3
Subscribe